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Abstract
Background: Fibroblast growth factor (FGF) family members are involved in the regulation of a
variety of biological phenomena. Because most of their activity is exerted via a signaling complex
composed of FGF, heparin/heparan sulfate and FGF receptor tyrosine kinase, it is important to
study the dynamic behavior of all the molecules in the complex without disturbing their interaction
or activity.
Findings: We used E. coli to express biologically active human FGF1 tagged at its C-terminus with
myc-(His)6, V5-(His)6 or 3xFLAG-(His)6. We found that the tagged FGF1s had affinities for heparin
that were similar to that of the native form. The tagged FGF1s also exhibited mitogenic activity
similar to that of the native form. Apparently, the tags do not interfere with the formation of the
three-member complex involving FGF1, FGF receptor and heparan sulfate/heparin.
Conclusion: Tagged FGF1s should be useful for investigating the dynamic behavior of FGF1 in the
context of its three-member signaling complex and other molecular complexes.
Findings
Background
Epitope tags are frequently introduced when expressing
recombinant proteins, as they make it easy to purify and
detect proteins of interest. However, addition of exoge-
nous amino acids can alter the properties of proteins,
including their affinity for other biomolecules and their
biological activities [1]. Nevertheless, the effect of intro-
ducing an epitope tag on the activity of a protein of inter-
est has rarely been addressed.
Fibroblast growth factors (FGFs) are multifunctional pro-
teins that play important roles in many biological phe-
nomena. Their effects are elicited mainly through
simultaneously binding to various cell surface FGF recep-
tors (FGFRs) and heparan sulfate sugar chains. In order to
analyze the structural features of the resultant three-mem-
ber complexes, we considered it useful to label each mem-
ber with a different epitope tag. Because such analyses
would require biologically active FGF1 to be tagged in var-
ious formats, we developed those proteins and report
some of their characteristics here.
Methods
Construction of cDNAs
The strategy for constructing cDNAs encoding chimeric
FGF1s is depicted schematically in Fig. 1, and the primers
used are listed in Table 1. Human FGF1 cDNA was cloned
into pET-3c vector as described previously [2]. To generate
cDNA encoding the chimeric proteins, PCR was carried
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out using the plasmid as a template with #127 serving as
the forward primer and #619 (for V5-(His)6 tag) or #397
(for myc-(His)6 tag) serving as the reverse primer. To gen-
erate the cDNA encoding V5-(His)6 tag, pAc5.1/V5-His
vector (Invitrogen) served as the template with primers
#620 and #301. For cDNA encoding myc-(His)6  tag,
pcDNA3.1(-)-myc-His vector (Invitrogen) served as the
template with primers #395 and #396.
To create a cDNA encoding 3xFLAG-(His)6, PCR was car-
ried out with primers #468 and #469 in the presence of
two megaprimers, #466 and #467, which served as the
template. The product was digested with Xho I and Apa I
and cloned into predigested pcDNA3.1(+), yielding plas-
mid 3xFLAG-(His)6/pcDNA3.1(+). The open reading
frame for FGF1 was then amplified using #476 and #477,
digested with EcoR I and Xho I, and inserted into predi-
gested 3xFLAG-(His)6/pcDNA3.1(+). Using this plasmid
as a template, PCR was then carried out with primers #117
and #537 to generate cDNA encoding the 3'-part of FGF1-
3xFLAG-(His)6. For the 5'-part, PCR was carried out using
FGF1/pET-3c as template with primers #127 and #178.
Once the first round PCR products were purified, overlap
extension PCR was carried out to generate the intended
cDNAs encoding the chimeric FGF1s. For FGF1-V5-(His)6,
the PCR products of #127/#619 and #620/#301 were
mixed as templates, and second round PCR was carried
out using primers #127 and #537. In the same way, for
FGF1-myc-(His)6, the products of #127/#397 and #395/
#396 were mixed as the template, and second round PCR
was carried out using primers #127 and #396. For FGF-1-
3xFLAG-(His)6, the PCR products of #127/#178 and
#117/#537 were mixed as the template, and second round
PCR was carried out using primers #127 and #537.
Once the full-length cDNAs encoding the chimeric pro-
teins were generated, the DNA for the open reading frame
was excised using Nde I/Bgl II and ligated into pET-3c vec-
tor (Novagen) predigested with Nde I/BamH I. The cDNA
Table 1: Primers used in this study
No. for./rev. sequence site
#127 forward 5'-gta ata cga ctc act ata ggg-3' vector primer
#619 reverse 5'-acc ttc atc aga aga gac tgg cag-3' FGF1/3' + V5-(His)6/5'
#397 reverse 5'-cga gct cgg atc aga aga gac tgg cag-3' FGF1/3' + myc-(His)6/5'
#620 forward 5'-tct gat gaa ggt aag cct atc cct-3' FGF1/3' + V5-(His)6/5'
#301 reverse 5'-tag aag gca cag tcg agg-3' vector primer
#395 forward 5'-cca gtc tct tct gat ccg agc tcg gta cca-3' FGF1/3' + myc-(His)6/5'
#396 reverse 5'-gct ctA GAT CTt caa tga tga tga tga tga tgg tc-3' myc-(His)6/3' + Bgl II
#468 forward 5'-cag ccg CTC GAG a-3' Xho I + 3xFLAG-(His)6/5'
#469 reverse 5'-tgc GGG CCC tca a-3' 3xFLAG-(His)6/5' + Apa I
#466 forward 5'-ccg CTC GAG act aca aag acc atg acg gtg att ata aag atc atg aca tcg act aca ag-3' megaprimer/5'
#467 reverse 5'-tgc GGG CCC tca atg gtg atg gtg atg atg acc ctt gtc atc gtc atc ctt gta gtc ga-3' megaprimer/3'
#476 forward 5'-cgG AAT TCc cac cat gtc ccg ggg agc-3' EcoR I + FGF1/5'
#477 reverse 5'-ccg CTC GAG cat cag aag aga ctg gca g-3' FGF1/3' + Xho I
#117 forward 5'-tct tcc gat aga ctg cgt cg-3' FGF1
#537 reverse 5'-gaA GAT CTc ttc aat ggt gat ggt gat gat gac c-3' (His)6/3' + Bgl II
#178 reverse 5'-agc ccg tcg gtg tcc atg gc-3' FGF1
Note that the capital letters indicate the recognition sequence of restriction enzymes.
Schematic diagram depicting the strategy for plasmid con- struction Figure 1
Schematic diagram depicting the strategy for plas-
mid construction. Complementary DNAs encoding FGF1 
and V5-(His)6 tag (a), myc-(His)6 tag (b) or 3xFLAG-(His)6 tag 
(c) were separately amplified, and the products were mixed 
and used as templates for overlap extension PCR. The 
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sequences were verified to be the intended sequences
using an ABI310 genetic analyzer. The expected numbers
of amino acid residues for native FGF1, FGF1-myc-(His)6,
FGF1-3xFLAG-(His)6 and FGF1-V5-(His)6 were 136, 165,
167 and 160, respectively.
Expression and semipurification of the recombinant FGF1
Expression vectors generated as described above were
used to transform Escherichia coli strain BL21(DE3)/pLysS
cells (Novagen), after which positive clones were selected.
After preincubating the cells for 3 h at 37°C, protein
expression was induced by addition of IPTG (final con-
centration: 1 mM), and the incubation was continued for
an additional 4 h at 37°C. The cells were then collected by
centrifugation and suspended in GET buffer (10 mM glu-
cose, 10 mM EDTA, 50 mM Tris-HCl, pH 7.4). The cell
walls of the suspended cells were disrupted by freeze/thaw
and sonication, after which the resultant lysate was fil-
tered (0.45 μm), and the salt concentration was adjusted
to 0.5 M. Heparin-Sepharose (Amersham Bioscience)
beads were then added, and the mixture was incubated for
18 h at 4°C. The resin was then packed into a small col-
umn and washed extensively with wash buffer (10 mM
Tris-HCl, pH 7.4, 500 mM NaCl), after which the bound
protein was eluted with elution buffer (10 mM Tris-HCl,
pH 7.4, 2.0 M NaCl). The peak fractions (judged from the
absorbance at 280 nm) were combined and subjected for
further analysis.
Gel electrophoresis and immunoblot analysis
Semipurified recombinant FGF1s were resolved by SDS-
PAGE (12.5%) and stained with Coomasie brilliant blue
(CBB) or transferred to nitrocellulose membranes (Sch-
leicher & Schuell BioScience Inc.) for immunostaining.
The membranes were probed with monoclonal anti-FGF1
(mAb1; 1 μg/ml) [3], anti-myc (1/5,000 dilution; Invitro-
gen), anti-FLAG (M2; 10 μg/ml; Sigma) or anti-V5 (1/
2,000 dilution; Invitrogen) antibodies in Tris-buffered
saline (TBS: 10 mM Tris-HCl, 0.15 M NaCl, pH 7.4) con-
taining 5% skim milk (SM), or monoclonal anti-His anti-
body (anti-penta-His; 0.2 μg/ml; QIAGEN) in TBS
containing 3% bovine serum albumin (BSA). HRP-conju-
gated goat anti mouse IgG (1/10,000 dilution; Zymed) in
TBS with 5% SM served as the secondary antibody for all
primary antibodies except anti-His. For anti-His, the same
secondary antibody (1/10,000 dilution) was used in TBS
with 5% BSA. The blots were visualized using an ECL
western blotting detection system (Amersham Bioscience)
according to the manufacturer's instructions.
Heparin affinity analyzed with HPLC
The affinities of the semipurified proteins for heparin
were analyzed using a Toso-HPLC system equipped with
a TSKguardgel Heparin-5PW column (6 mm ID × 1 cm).
Tris-HCl buffer (pH 7.4) containing 0.15 M NaCl (buffer
A) or 2.0 M NaCl (buffer B) were used as the effluents, the
flow rate was 1.0 ml/min, and the eluate was fractionated
into 0.5-ml fractions. The elution profile was monitored
based on the absorbance at 280 nm. The salt concentra-
tion of each fraction was calibrated based on its conduc-
tivity.
Aliquots of the HPLC fractions were subjected to dot-blot
analysis. Samples were loaded onto a nitrocellulose filter
in a BioRad dot blotting system and then blocked with 5%
SM. As the antibody mAb1 preferentially binds to dena-
tured FGF1, the filter was first incubated in 2% SDS and
100 mM 2-mercaptoethanol for 30 min at 70°C, after
which is was blocked in 5% SM again and immunostained
using mAb1 as described above.
Assaying the mitogenic activity of FGF1
Ba/F3 cells were purchased from RIKEN. An expression
vector encoding the FGFR1-IIIc was a generous gift from
Dr. D. M. Ornitz (Washington Univ., St. Louis, MO). The
vector was transfected into Ba/F3 cells by electroporation,
after which neo-resistant clones were selected. Ba/F3 cells
expressing FGFR1-IIIc (designated FGFR1c-Ba/F3 cells)
were cultivated in RPMI1640 supplemented with 10%
fetal bovine serum, 50 ng/ml recombinant FGF1, 5 μg/ml
heparin and 0.5 mg/ml geneticin. To assay mitogenic
activity, FGFR1c-Ba/F3 cells were seeded into a microplate
to a density of 6.6 × 103 cells/well and incubated with the
indicated amount of each tagged FGF1 and 10% FCS in
the presence or absence of heparin (10 μg/ml). After 48 h,
TetraColor ONE (Seikagaku Kogyo, Tokyo) was added,
and the cells were incubated for an additional 4 h, after
which the absorbance at 450 nm was measured.
Results and discussion
Construction and expression of tagged FGF1
Using overlap extension PCR, we constructed a set of
cDNAs encoding FGF1 with various tags. The proteins
expressed in E. coli had the expected molecular weights
and were semipurified by heparin affinity column chro-
matography. Subsequent SDS-PAGE revealed that each
construct was purified to homogeneity, as indicated by
the single band after CBB staining (Fig. 2a). A monoclonal
anti-FGF1 antibody (mAb1) recognized all of the proteins
expressed (Fig. 2b). By contrast, monoclonal antibodies
against (His)6-tag, myc-tag, FLAG-tag and V5-tag specifi-
cally recognized the correspondingly tagged FGF1, but not
FGF1s with different tags (Fig. 2c–f). The minor band
accompanying FGF1-3xFLAG-(His)6 detected with anti-
FLAG antibody (Fig. 2e) is likely a partially N-truncated
fragment of the intact protein, since the tag is at the C-ter-
minus.BMC Research Notes 2008, 1:42 http://www.biomedcentral.com/1756-0500/1/42
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Heparin-affinity of the tagged FGFs
To determine their affinity for heparin, batch-purified
FGF1s were subjected to heparin affinity HPLC and eluted
with a linear NaCl gradient. A single absorbance peak at
280 nm was detected for each tagged FGF1 (Fig. 3a), and
the FGF1 constructs in the peak fractions were confirmed
by dot blot analysis using monoclonal anti-FGF1 anti-
body (Fig. 3b). We found that FGF1, FGF1-myc-(His)6,
FGF1-3xFLAG-(His)6  and FGF1-V5-(His)6  were eluted
from heparin Sepharose with 1.24, 1.09, 1.17 and 1.17 M
NaCl, respectively, which is in good agreement with ear-
lier reports that the NaCl concentration required for FGF1
elution from heparin is 1–1.2 M NaCl [4].
Because Lacy and Sanderson previously reported that
(His)6  tag enhanced the affinity of Sp17 protein for
heparan sulfate [5], we analyzed the effect of various tags
on the affinity of FGF1 protein for heparin. FGF1 has a
strong affinity for heparin/heparan sulfate, and the inter-
action may be critically important for its biological activ-
ity. We found that the myc-(His)6, 3xFLAG-(His)6 and V5-
(His)6 tags used in this study had little effect on the affin-
ity of FGF1 for heparin. Given that the three-dimensional
structure of FGF1 indicates that its N- and C-termini are
flexible and outside the β-barrel structure important for
receptor binding and heparin affinity [6], it is likely that
addition of a tag at the C-terminus has no effect on the
protein's affinity to heparin/heparan sulfate.
Mitogenic activity of tagged FGF1
We also investigated the ability of tagged FGF1 to stimu-
late proliferation of FGFR1c-Ba/F3 cells [7]. As shown in
Fig. 4a, the mitogenic activities of FGF1s tagged with myc-
(His)6, 3xFLAG-(His)6 or V5-(His)6 were indistinguisha-
ble from those of native FGF1. Moreover, statistical anal-
ysis revealed no significant difference between any of the
FGF1s. These results strongly suggest that in the presence
of heparin these tagged FGF1s have affinities for cell sur-
face FGFR1-IIIc that are similar to native FGF1. In addi-
tion, like native FGF1, they exhibited no activity in the
Electrophoresis and immunoblot analysis of the expressed  proteins Figure 2
Electrophoresis and immunoblot analysis of the 
expressed proteins. FGF1 (lane 1), FGF1-myc-(His)6 (lane 
2), FGF1-3xFLAG-(His)6 (lane 3) and FGF1-V5-(His)6 (lane 4) 
were expressed by E. coli and semipurified by heparin-Sepha-
rose affinity chromatography. The eluate was subjected to 
SDS-PAGE and stained with CBB (a). After electrophoresis, 
the separated proteins were transferred to nitrocellulose 
membranes and immunoblotted using monoclonal anti-FGF1 
(b), anti-His (c), anti-myc (d), anti-FLAG (e) or anti-V5 (f) 
antibodies. Positions of the molecular weight markers are 
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HPLC analysis of the affinity of semipurified FGF1s for  heparin Figure 3
HPLC analysis of the affinity of semipurified FGF1s 
for heparin. The elution profiles of FGF1, FGF1-myc-(His)6, 
FGF1-3xFLAG-(His)6 and FGF1-V5-(His)6 are illustrated in 
(a). NaCl concentration was gradually increased as illustrated 
at the top, and the absorbance at 280 nm was monitored. An 
aliquot of the peak fraction was also subjected for dot-blot 
analysis using anti-FGF1 monoclonal antibody (b).
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absence of heparin, nor was any mitogenic activity
detected in the absence of FGF1, despite the presence of
heparin (Fig. 4b).
We have shown here that introduction of a myc-(His)6,
3xFLAG-(His)6 or V5-(His)6 tag at the C-terminus of FGF1
had little or no effect on the growth factor's affinity for
heparin and its mitogenic activity toward cells expressing
FGFR1-IIIc. Apparently, FGF1, FGFR and heparin are able
to form an active signaling complex on the cell surface,
despite the presence of a C-terminal tag. These tagged
FGF1s should be useful for investigating the dynamic
behavior of FGF1 in the context of its three-member sign-
aling complex and other molecular complexes.
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Mitogenic activity of FGF1s towards FGFR1c-Ba/F3 cells Figure 4
Mitogenic activity of FGF1s towards FGFR1c-Ba/F3 
cells. (a) FGFR1c-Ba/F3 cells were cultivated for 48 h with 
the indicated concentrations of FGF1s in the presence of 10 
μg/ml heparin (closed symbols). TetraColor ONE was then 
added, and the cells were incubated for an additional 4 h, 
after which the absorbance at 450 nm was measured. No 
mitogenic activity was seen in the absence of heparin (open 
symbols). (b) In the absence of the FGF1s, no activity was 
observed, despite the presence of heparin. The data pre-
sented are the averages and standard deviations of a tripli-
cate experiment. Independent experiments were performed 
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